Lincoln Pharma
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Lincoln Pharmaceuticals is navigating a strategic transition towards a diversified, high-value portfolio, focusing on chronic and lifestyle segments. Management's emphasis on R&D, with over 100 active development programs and a robust pipeline of 700 products, positions the company for sustained revenue growth, targeting Rs. 1,000 crore within three years. This aligns with Vista's forecast of stable revenue growth and improving margins, supported by favorable currency depreciation and resilient demand in chronic therapies. However, execution risks related to regulatory compliance and logistics volatility present challenges. The Indian pharmaceutical industry is expanding, benefiting from improving pricing power and a strong export market, which further supports Lincoln's outlook. Over the next 12-24 months, key opportunities include leveraging international certifications for market expansion and capitalizing on the growing demand for affordable generics. Conversely, watchpoints include rising input costs, pricing pressures in the U.S. market, and increased competition in the biosimilars space, which could impact profitability and market share
Why We Like This Stock
- Management's focus on high-value product lines and geographic expansion is expected to drive revenue growth
- A strong R&D pipeline with over 700 products supports long-term growth and market competitiveness
- Favorable currency depreciation enhances revenue potential for export-oriented operations
Things To Watch Out For
- Execution risks related to regulatory compliance in international markets could hinder growth
- Rising input costs and pricing pressures in the U.S. market may impact margins
- Increased competition in the biosimilars space poses a threat to profitability
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 581 | 623 | 671 | 710 | 789 |
| Profit Before Tax (Cr.) | 121 | 107 | 116 | 136 | 148 |
| PBT Margin | 20.8% | 17.2% | 17.3% | 19.2% | 18.7% |
| Net Profit (Cr.) | 96 | 83 | 88 | 104 | 112 |
| Earnings Per Share | 47.8 | 41.4 | 43.9 | 51.7 | 56.0 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia. Lincoln Pharmaceuticals Limited was incorporated in 1979 and is based in Ahmedabad, India.